REHOVOT, Israel and JERSEY CITY, New Jersey, September 29
/PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG) has been
named this year's winner of the Medical-Biotech category in the Wall Street
Journal Technology Innovation Awards.
The Wall Street Journal received more than 700 entries for the Innovation
Awards, and a Journal editor narrowed the field down to the 162 that were
scored by the judges. Judges looked for innovations that broke new ground in
their fields and that demonstrated some measurable impact. Only 4% of the
entries received the final award in 16 different categories.
'We are excited to receive this prestigious award in recognition of the
groundbreaking microRNA-based diagnostic tests that are being developed at
Rosetta Genomics,' said Amir Avniel, President and CEO of the company.
'Rosetta Genomics has been one of the first companies to recognize the vast
potential microRNAs hold for clinical applications, and we expect the first
microRNA-based tests to be launched later this year.'
About microRNAs
MicroRNAs (miRNAs) are recently discovered, naturally occurring, small
RNAs that act as master regulators and have the potential to form the basis
for a new class of diagnostics and therapeutics. Since many diseases are
caused by the abnormal activity of proteins, the ability to selectively
regulate protein activity through microRNAs could provide the means to treat
a wide range of human diseases. In addition, microRNAs have been shown to
have different expression in various pathological conditions. As a result,
these differences may provide for a novel diagnostic strategy for many
diseases.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA.
Founded in 2000, the company's integrative research platform combining
bioinformatics and state-of-the-art laboratory processes has led to the
discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong IP position and proprietary platform technologies,
Rosetta Genomics is working on the application of these technologies in the
development of a full range of microRNA-based diagnostic and therapeutic
tools, focusing primarily on cancer and various women's health indications.
The first test based on the company's technology, differentiating squamous
from non squamous non small cell lung cancer, is now approved through
Columbia University Medical Center's High Complexity Molecular Pathology
Laboratory.
